Colonic mucosal fatty acid synthase as an early biomarker for colorectal neoplasia: Modulation by obesity and gender

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 11, 2014, Pages 2413-2421

  Dela Cruz, Mart ^a   Wali, Ramesh K ^a   Bianchi, Laura K ^b   Radosevich, Andrew J ^c   Crawford, Susan E ^d   Jepeal, Lisa ^a   Goldberg, Michael J ^b   Weinstein, Jaclyn ^a   Momi, Navneet ^a   Roy, Priya ^a   Calderwood, Audrey H ^a   Backman, Vadim ^c   Roy, Hemant K ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c Northwestern University   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; FATTY ACID SYNTHASE; MESSENGER RNA; TUMOR MARKER;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CANCER RISK; COLON MUCOSA; COLON POLYPOSIS; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RAT; RECTUM BIOPSY; RECTUM MUCOSA; SEX DIFFERENCE; ANIMAL; COLORECTAL TUMOR; COMPLICATION; DISEASE MODEL; METABOLISM; PATHOLOGY;

ANIMALS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FATTY ACID SYNTHASES; HUMANS; MALE; OBESITY; RATS;

EID: 84920108752     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0026     Document Type: Article

References (44)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Roy HK, Backman V, Goldberg MJ. Colon cancer screening: the good, the bad, and the ugly. Arch Intern Med 2006;166:2177-9.
3. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology 2013;144: 799-807.
4. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008;25:2097-116.
5. Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann BJ, PeeD, et al. Colorectal cancer risk prediction tool for whitemen and women without known susceptibility. J Clin Oncol 2009;27:686-93.
6. Roy HK, Gomes A, Turzhitsky V, Goldberg MJ, Rogers J, Ruderman S, et al. Spectroscopic microvascular blood detection from the endoscopically normal colonic mucosa: biomarker for neoplasia risk. Gastroenterology 2008;135:1069-78.
7. Wali RK, Roy HK, KimYL, Liu Y, Koetsier JL, Kunte DP, et al. Increased microvascular blood content is an early event in colon carcinogenesis. Gut 2005;54:654-60.
8. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77.
9. Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, et al. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst 2012;104:415-20.
10. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, et al. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 2009;136:1242-50.
11. Qi W, Fitchev PS, Cornwell ML, Greenberg J, Cabe M, Weber CR, et al. FOXO3 growth inhibition of colonic cells is dependent on intraepithelial lipid droplet density. J Biol Chem 2013;288:16274-81.
12. Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS, et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res 2008;68:1732-40.
13. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut 2013;62:933-47.
14. Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, et al. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc Natl Acad Sci U S A 2007;104:4036-41.
15. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim 1981;15:57-9.
16. Roy HK, Bianchi LK. Differences in colon adenomas and carcinomas among women and men: potential clinical implications. JAMA 2009;302:1696-7.
17. Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol 2007;13:4199-206.
18. Brandstedt J, Wangefjord S, Nodin B, Gaber A, Manjer J, Jirstrom K. Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study. Biol Sex Differ 2012;3:23.
19. Notarnicola M, Tutino V, Calvani M, Lorusso D, Guerra V, Caruso MG. Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage. J Gastrointest Cancer 2012;43:508-11.
20. Paun BC, Kukuruga D, Jin Z, Mori Y, Cheng Y, Duncan M, et al. Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. Cancer 2010;116:4495-501.
21. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-97.
22. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 2009;18:1695-8.
23. Zisman AL, Nickolov A, Brand RE, Gorchow A, Roy HK. Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco: implications for screening. Arch Intern Med 2006;166:629-34.
24. Notarnicola M, Altomare DF, Calvani M, Orlando A, Bifulco M, D'Attoma B, et al. Fatty acid synthase hyperactivation in human colorectal cancer: relationship with tumor side and sex. Oncology 2006;71:327-32.
25. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008;26:5713-20.
26. Long QQ, Yi YX, Qiu J, Xu CJ, Huang PL. Fatty acid synthase (FASN) levels in serum of colorectal cancer patients: correlation with clinical outcomes. Tumour Biol 2014;35:3855-9.
27. Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB, Rinaldi S, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010;172:407-18.
28. Roy HK, Gomes AJ, Ruderman S, Bianchi LK, Goldberg MJ, Stoyneva V, et al. Optical measurement of rectal microvasculature as an adjunct to fl exible sigmoidosocopy: gender-specific implications. Cancer Prev Res 2010;3:844-51.
29. Tiwari AK, Crawford SE, Radosevich A, Wali RK, Stypula Y, Kunte DP, et al. Neo-angiogenesis and the premalignant micro-circulatory augmentation of early colon carcinogenesis. Cancer Lett 2011;306: 205-13.
30. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol 2012;23:352-61.
31. Payne CM, Holubec H, Bernstein C, Bernstein H, Dvorak K, Green SB, et al. Crypt-restricted loss and decreased protein expression of cytochrome C oxidase subunit I as potential hypothesis-driven biomarkers of colon cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14: 2066-75.
32. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
33. Wang X, Chorley BN, Pittman GS, Kleeberger SR, Brothers J II, Liu G, et al. Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer. PLoS ONE 2010;5:e11934.
34. Ong ES, Zou L, Li S, Cheah PY, Eu KW, Ong CN. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis. Mol Cell Proteomics 2010 Feb 10. [Epub ahead of print].
35. Lau DS, Archer MC. Fatty acid synthase is over-expressed in large aberrant crypt foci in rats treated with azoxymethane. Int J Cancer 2009;124:2750-3.
36. Kearney KE, Pretlow TG, Pretlow TP. Increased expression of fatty acid synthase in human aberrant crypt foci: possible target for colorectal cancer prevention. Int J Cancer 2009;125:249-52.
37. Yun KE, Chang Y, Jung HS, Kim CW, Kwon MJ, Park SK, et al. Impact of body mass index on the risk of colorectal adenomain a metabolically healthy population. Cancer Res 2013;73:4020-7.
38. Li N, Bu X, Tian X, Wu P, Yang L, Huang P. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway. Nutr Cancer 2012;64:864-70.
39. Ikeda K, Mutoh M, Teraoka N, Nakanishi H,Wakabayashi K, Taguchi R. Increase of oxidant-related triglycerides and phosphatidylcholines in serum and small intestinal mucosa during development of intestinal polyp formation in Min mice. Cancer Sci 2011;102:79-87.
40. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6:551-62.
41. Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog 2004;41:164-78.
42. Orita H, Coulter J, Lemmon C, Tully E, Vadlamudi A, Medghalchi SM, et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res 2007;13:7139-45.
43. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004;64:2070-5.
44. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006;98:920-31.